Table 1 Baseline characteristics of matched subjects according to the presence of diabetes.

From: Differential association of ezetimibe-simvastatin combination with major adverse cardiovascular events in patients with or without diabetes: a retrospective propensity score-matched cohort study

 

Diabetes

No diabetes

Diabetes vs. No diabetes

S + E (n = 545)

S (n = 545)

P

S + E (N = 1292)

S (N = 1292)

P

P

Age (years)

70.3 ± 0.9

70.3 ± 0.9

0.997

67.7 ± 10.0

67.7 ± 10.9

0.985

<0.001

Men (%)

298 (54.7)

295 (54.1)

0.855

624 (48.3)

640 (49.5)

0.529

0.002

BMI (kg/m2)

25.1 ± 3.1

25.0 ± 3.4

0.776

24.4 ± 3.0

24.4 ± 3.1

0.681

<0.001

Current smoker

91 (16.7)

85 (15.6)

0.621

172 (13.3)

165 (12.8)

0.683

0.013

HTN

317 (58.2)

319 (58.5)

0.902

553 (42.8)

546 (42.3)

0.781

0.551

CKD

20 (3.7)

17 (3.10)

0.616

23 (1.8)

21 (1.6)

0.761

0.001

Previous UA

55 (10.1)

46 (8.4)

0.347

71 (5.5)

67 (5.2)

0.726

<0.001

Previous MI

29 (5.3)

27 (5.0)

0.784

40 (3.1)

37 (2.9)

0.729

0.001

Previous stroke

46 (8.4)

57 (10.5)

0.255

114 (8.8)

116 (9.0)

0.890

0.597

Aspirin

378 (69.4)

367 (67.3)

0.474

814 (63.0)

803 (62.2)

0.655

0.001

Clopidogrel

187 (34.3)

181 (33.2)

0.701

368 (28.5)

404 (31.3)

0.122

0.020

Beta blocker

267 (49.0)

254 (46.6)

0.431

482 (37.3)

491 (38.0)

0.715

<0.001

ACEi/ARB

311 (57.1)

295 (54.1)

0.329

551 (42.7)

539 (41.7)

0.633

<0.001

Insulin

100 (18.4)

92 (16.9)

0.525

0 (0.0)

0 (0.0)

n/a

n/a

Metformin

287 (52.7)

290 (53.2)

0.856

0 (0.0)

0 (0.0)

n/a

n/a

Sulfonylurea

234 (42.9)

226 (41.5)

0.624

0 (0.0)

0 (0.0)

n/a

n/a

Other DM med*

181 (33.2)

182 (33.4)

0.949

0 (0.0)

0 (0.0)

n/a

n/a

TC (mg/dl)

178 ± 48

179 ± 51

0.814

188 ± 50

188 ± 48

0.685

<0.001

LDL-C (mg/dl)

101 ± 40

101 ± 40

0.842

110 ± 43

111 ± 39

0.763

<0.001

HDL-C (mg/dl)

46 ± 13

46 ± 11

0.753

50 ± 12

50 ± 12

0.949

<0.001

Triglyceride (mg/dl)

163 ± 136

161 ± 109

0.773

141 ± 98

143 ± 82

0.573

<0.001

Fasting glucose (mg/dl)

130 ± 43

129 ± 39

0.716

100 ± 18

101 ± 22

0.399

<0.001

HbA1C (% [mmol/mol])

7.3[56] ± 2.5

7.2[55] ± 1.3

0.364

n/a

n/a

n/a

n/a

Creatinine (mg/dl)

1.03 ± 0.45

1.01 ± 0.36

0.496

0.94 ± 0.44

0.96 ± 0.47

0.188

<0.001

  1. Notes: Data are presented as mean ± standard deviation or number (%) as appropriate.
  2. Abbreviations: ACEi/ARB, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker; BMI, body mass index;; CKD, chronic kidney disease; DM, diabetes mellitus; HDL-C, high density lipoprotein cholesterol; HTN, hypertension; LDL-C, low density lipoprotein cholesterol; MI, myocardial infarction; S, simvastatin 20 mg alone; S + E, Combination of simvastatin 20 mg + ezetimibe 10 mg; TC, total cholesterol; UA, unstable angina.
  3. *Composite of dipeptidyl-peptidase IV inhibitors, peroxisome proliferator-activated receptor gamma agonists, glucagon-like peptide-1 agonists, and alpha-glucosidase inhibitors.
Back to article page